Aurobindo Pharma is planning to produce generic version of the antiviral drug Molnupiravir at its domestic manufacturing facilities which have been approved by global agencies like the USFDA and UKMHRA. Molnupiravir is used in the treatment of COVID-19. The company would sell the product under the brand 'Molnaflu' and has adequate capacities to meet the global demand across the 100 plus Low and Middle-Income Countries (LMIC).
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
